Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Trial to Evaluate an mRNA-Based Cancer Immunotherapy in Multiple Solid Tumors

Next Previous
Trial Profile

A Clinical Trial to Evaluate an mRNA-Based Cancer Immunotherapy in Multiple Solid Tumors

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti-cancer mRNA immunotherapies BioNTech/Sanofi (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions

Most Recent Events

  • 16 Jan 2019 New trial record
  • 04 Jan 2019 According to a BioNTech media release, Sanofi is pleased to be initiating this trial of first mRNA-based cancer immunotherapy in collaboration with its partners at BioNTech.
  • 04 Jan 2019 According to a BioNTech media release, Sanofi is investing EUR 80 million in equity in BioNTech as they extend its research collaboration initiated in late 2015.Simultaneously BioNTech has entered into an agreement with Sanofi to co-develop the first cancer immunotherapy candidate from the collaboration that is entering clinical testing in multiple solid tumors. This follows BioNTechs decision from early 2018 to exercise one of its option rights under the 2015 research collaboration.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top